Short Interest in Astellas Pharma Inc. (OTCMKTS:ALPMY) Rises By 20.8%

Astellas Pharma Inc. (OTCMKTS:ALPMY) was the recipient of a significant growth in short interest in February. As of February 28th, there was short interest totalling 57,000 shares, a growth of 20.8% from the February 13th total of 47,200 shares. Approximately 0.0% of the shares of the company are short sold. Based on an average daily volume of 225,700 shares, the short-interest ratio is currently 0.3 days.

Astellas Pharma Price Performance

ALPMY stock opened at $9.96 on Tuesday. The firm has a 50 day moving average of $9.66 and a 200-day moving average of $10.58. The company has a current ratio of 1.04, a quick ratio of 0.80 and a debt-to-equity ratio of 0.39. Astellas Pharma has a 12 month low of $9.05 and a 12 month high of $13.14. The firm has a market capitalization of $18.02 billion, a P/E ratio of -45.26 and a beta of 0.29.

Astellas Pharma (OTCMKTS:ALPMY) last released its quarterly earnings data on Tuesday, February 4th. The company reported $0.30 EPS for the quarter. Astellas Pharma had a negative net margin of 3.10% and a positive return on equity of 13.69%. As a group, sell-side analysts predict that Astellas Pharma will post 0.42 earnings per share for the current fiscal year.

Astellas Pharma Company Profile

Astellas Pharma Inc manufactures, markets, and imports and exports pharmaceuticals in Japan and internationally. The company provides XTANDI, a treatment for prostate cancer; XOSPATA, a treatment for patients who have relapsed or refractory acute myeloid leukemia with a FLT3 mutation; and PADCEV, a treatment for patients with metastatic urothelial cancer.